Pre-exposure prophylaxis for HIV-1 prevention does not diminish the pregnancy prevention effectiveness of hormonal contraception

AIDS

Volumn 28, Issue 12, 2014, Pages 1825-1830

  Murnane, Pamela M ^a,b   Heffron, Renee ^a,b   Ronald, Allan ^c   Bukusi, Elizabeth A ^c,d   Donnell, Deborah ^b,h   Mugo, Nelly R ^b,e,f   Were, Edwin ^g   Mujugira, Andrew ^a,b   Kiarie, James ^b,e,f   Celum, Connie ^a,b   Baeten, Jared M ^a,b  

^a Department of Epidemiology ^*  (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

^d KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^e UNIVERSITY OF NAIROBI   (Kenya)

^f KENYATTA NATIONAL HOSPITAL   (Kenya)

^g MOI UNIVERSITY   (Kenya)

^h Fred Hutchinson Cancer Research Center   (United States)

Author keywords

HIV 1 prevention; hormonal contraception; women

Indexed keywords

EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; INJECTABLE CONTRACEPTIVE AGENT; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; CONTRACEPTIVE AGENT; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; FEMALE; FOLLOW UP; GYNECOLOGICAL AND OBSTETRIC IMPLANT; HETEROSEXUALITY; HORMONAL CONTRACEPTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; ORAL CONTRACEPTIVE USE; PREGNANCY; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; UNPROTECTED SEX; CONTRACEPTION; HIV INFECTIONS; MALE; PRE-EXPOSURE PROPHYLAXIS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; CONTRACEPTION; CONTRACEPTIVE AGENTS, FEMALE; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; PLACEBOS; PRE-EXPOSURE PROPHYLAXIS; PREGNANCY; TREATMENT OUTCOME;

EID: 84904216424     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000290     Document Type: Article

References (17)

1. Heffron R, Donnell D, Rees H, Celum C, Mugo N, Were E, et al. Use of hormonal contraceptives and risk of HIV-1 transmission a prospective cohort study. Lancet Infect Dis 2012 1219-26.
2. Polis CB, Curtis KM. Use of hormonal contraceptives and HIV acquisition in women a systematic review of the epidemiological evidence. Lancet Infect Dis 2013 13797-808.
3. Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012 367411-422.
4. FHI 360. Pregnancy and contraceptive effectiveness in the FEMPrEP trial. http//www.fhi360.org/sites/default/files/media/docu ments/ FEMPrEPFactSheetPregnancyContraceptiveEffectivenes. pdf. [Last accessed 1 November 2013].
5. Kearney BP, Mathias A. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives. Pharmacotherapy 2009 29924-929.
6. Coleman J, Chaturvedula A, Hendrix C, MTN-001 Protocol Team. Method of hormonal contraception is associated with lower tenofovir concentration in healthy women (MTN-001) implications for preexposure prophylaxis, abstract FRLBC03. Presented at XIX International AIDS Conference. Washington, DC, USA July 22-27.
7. Maskew M, Westreich D, Firnhaber C, Sanne I. Tenofovir use and pregnancy among women initiating HAART. AIDS 2012 262393-2397.
8. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012 367399-410.
9. Andersen PK, Gill RD. Cox's regression model for counting processes a large sample study. Ann Stat 1982 101033-1311.
10. Donnell DJ, Baeten JM, Hong T, Lingappa JR, Mujugira A, Nakku-Joloba E, et al. Correlation between pill counts and biologic effects in an HIV-1 prevention clinical trial implications for measuring adherence. AIDS Behav 2013 17632-639.
11. Mugo N, Hong T, Celum C, Donnell D, Bukusi E, Were E, et al. Pregnancy incidence and birth outcomes among African women in a clinical trial of preexposure prophylaxis the Partners PrEP Study, #WEAC0101. Presented at 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Kuala Lumpur, Malaysia 2013.
12. Ngure K, Heffron R, Mugo NR, Celum C, Cohen CR, Odoyo J, et al. Contraceptive method and pregnancy incidence among women in HIV-1-serodiscordant partnerships. AIDS 2012 26513-518.
13. Steiner MJ, Kwok C, Dominik R, Byamugisha JK, Chipato T, Magwali T, et al. Pregnancy risk among oral contraceptive pill, injectable contraceptive, and condom users in Uganda, Zimbabwe, and Thailand. Obstet Gynecol 2007 1101003-1009.
14. Andrews C, Gettie A, Russell-Lodrigue K, Moss L, Mohri H, Spreen W, et al. Long-acting parenteral formulation of GSK1265744 protects macaques against repeated intrarectal challenges with SHIV, #24LB. Presented at 20th Conference on Retroviruses and Opportunistic Infections. Atlanta, GA March 3-6, 2013.
15. Smith JM, Rastogi R, Teller RS, Srinivasan P, Mesquita PM, Nagaraja U, et al. Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc Natl Acad Sci USA 2013 11016145-16150.
16. Microbicide Trials Network. Phase III trial of dapivirine ring begins in Africa ASPIRE testing new HIV prevention approach for women. http//www.mtnstopshiv.org/node/4546. [Last accessed 10 November 2013].
17. Friend DR, Clark JT, Kiser PF, Clark MR. Multipurpose prevention technologies products in development. Antiviral Res 2013 100 (Suppl)S39-S47.